|
| | | | |
|
 | | THERAGENETICS APPOINTS ROBERT MCBURNEY, PH.D. AS EXECUTIVE VICE PRESIDENT | | | TheraGenetics Limited | | 23/09/2008 | | | TheraGenetics Limited, a personalized medicine diagnostics company that is developing and commercializing a portfolio of pharmacogenetic diagnostic tests to guide and improve the treatment of central nervous system (CNS) disorders, announced today the appointment of Robert N. McBurney, Ph.D., to Executive Vice President. In this newly created role, Dr. McBurney will be responsible for leading the company’s global business development and partnership strategy and will report to Richard Kivel, CEO of TheraGenetics.
“I have known Robert for many years through our mutual involvement in MIT’s entrepreneurship programs and it gives me great pleasure to welcome him to the TheraGenetics’ executive leadership team,” stated Richard Kivel, Chief Executive Officer of TheraGenetics. “His impressive background in the field of neuroscience will add tremendous value to the Company and enhance our commitment to bring personalized medicine diagnostics into clinical practice for critical CNS disorders by predicting patient response and side-effects to drug treatments.”
Dr. McBurney brings to TheraGenetics more than 20 years of experience in the biopharmaceutical industry. He most recently served as Senior Vice President, Research & Development and Chief Scientific Officer at BG Medicine, Inc., where he was responsible for overseeing the application of the company’s molecular systems analysis technology platform to provide solutions for the pharmaceutical industry and to discover biomarkers for development into molecular diagnostics. Prior to BG Medicine, he co-founded Differential Proteomics, Inc., a start-up biotechnology company focused on unlocking the potential of proteomics for use in drug discovery, clinical development and patient management. In addition, Dr. McBurney held the position of President at CeNeS Pharmaceuticals, Inc., served in several executive leadership roles of increasing responsibility at Cambridge NeuroScience, including Chief Executive Officer and President, and held medical research and academic positions at leading centers of excellence, including the Medical Research Council’s Neuroendocrinology Unit, Newcastle University, National Institutes of Health, and Cambridge University. He earned his Ph.D. and his B.Sc. in Physiology from the University of New South Wales in Sydney, Australia.
“I am truly excited to join TheraGenetics and bring my extensive management and leadership experience to the Company as we seek to develop new partnerships that will help advance our development of pharmacogenetic tests for CNS disorders, ” said Dr. McBurney. “Under Rich Kivel’s leadership, the Company has made tremendous progress towards its goal of linking genes to the successful treatment of specific CNS disorders and of realizing the promise of tailoring the right drug to the right patient.”
About TheraGenetics
TheraGenetics is a privately held, personalized medicine diagnostics company that is developing and commercializing a portfolio of pharmacogenetic diagnostic tests to guide and improve the treatment of CNS disorders thereby bringing the right medicine to the right patient. TheraGenetics was created in April 2006 as a spin-out of the Institute of Psychiatry at King's College London. Current investors include Swarraton Partners Ltd., Tudor Capital UK, IP Group PLC and Kinetique Biomedical Seed Fund. | |
|
| | | View similar articles: | | |
| | | |
|
 | People who viewed this article were also interested in |  | |  |
|
| Other articles from TheraGenetics Limited | | | |
|